Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MB0151
- Development stage
- Phase 2
- Lead developer
- Zhongshan Mainstream Source Biotechnology
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
MB0151 is a peptide-drug conjugate developed as a modulator of somatostatin receptor 2 (SSTR2). It is being investigated primarily for the treatment of advanced malignant solid neoplasms, including gastro-enteropancreatic neuroendocrine tumors, small cell lung cancer, and triple-negative breast cancer. The drug acts by targeting SSTR2, which is commonly expressed in certain tumor types. Its mechanism involves modulation of SSTR2 signaling pathways to exert anti-tumor effects. The drug is administered intravenously every two weeks in clinical studies and is currently undergoing Phase 1/2 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity[1][3][6].
- Brand names
- MB0151MB-0151MB 0151
- Other names
- MB0151MB-0151MB 0151
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on MB0151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MB0151.